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Background: Cutaneous bacterial infections are common in children and adults and frequently are caused by
Staphylococcus aureus (S. aureus). Treatment failures with topical agents are not uncommon and have been
shown to be secondary to bacterial resistance.
Objective: To determine clinical and bacteriological efﬁcacy of retapamulin ointment 1% in treatment of patients
with cutaneous bacterial infections caused by methicillin-resistant S. aureus (MRSA) and other bacteria.
Methods: Prospective, nonrandomized, uncontrolled, open label, single center trial conducted between April
2008 and November 2012 that evaluated efﬁcacy of retapamulin ointment 1% in the treatment of impetigo, fol-
liculitis, and otherminor soft tissue infections in children and adults. Fifty patients, who presented to a dermatol-
ogy outpatient clinic and were clinically diagnosed with impetigo, folliculitis, or minor soft tissue infection
suitable for treatment with a topical antibiotic, were screened. Thirty-eight patients were enrolled and received
treatment: topical retapamulin ointment 1% twice daily for 5 days. Seven patients wereMRSA positive and qual-
iﬁed for the primary efﬁcacy population. One patient withdrew due to an adverse event. Clinical and microbio-
logical exams were performed at baseline and follow-up 5 to 7 days later to assess clinical, microbiological,
and therapeutic responses. Primary outcome was clinical response at follow-up in primary efﬁcacy population
with MRSA isolated as the baseline pathogen. Secondary outcomes included clinical, microbiologic, and thera-
peutic responses in patients who were culture positive for any species of bacteria.
Results: Clinical response at follow-up in the primary efﬁcacy population (MRSA-positive patients) was not suf-
ﬁciently powered to demonstrate signiﬁcance; however, outcomes were excellent, with 7 of 7 patients demon-
strating clinical success (5 of 7) or clinical improvement (2 of 7) at follow-up. Barring lack of signiﬁcance due to
small total sample size for patients whowere culture positive for any species of bacteria (n=35), overall success
rates were favorable for clinical, microbiologic, and therapeutic responses with values of 66%, 97%, and 69%, re-
spectively. Adverse events (AEs) were mild or moderate in severity. No serious AEs were reported.
Conclusion: Safety proﬁle appears favorable given the lownumber of AEs. Study design limits conclusions that can
be drawn. Nevertheless, this study supports use of topical retapamulin 1% ointment in treatment of cutaneous
bacterial infections, particularly those caused by S. aureus, including MRSA.
© 2015 The Authors. Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).laxoSmithKline plc, Research
versity of Texas Medical School
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Impetigo, folliculitis, and other minor soft tissue infections are com-
mon in both children and adults. Impetigo is a superﬁcial skin infection
caused by bacteria and has been shown to be the most common infec-
tion in childrenworldwide (Rortveit and Rortveit, 2007). Staphylococcus
aureus and Streptococcus pyogenes (Group A Streptococcus) are the bac-
teria most commonly associated with this soft tissue infection (Yang
and Keam, 2008). S. aureus has recently been shown to be responsible
for most cases (70%), which is a change from years past when
S. pyogeneswas the primary pathogen leading to impetigo (Darmstadtologic Society. This is an open access article under the CC BY-NC-ND license (http://
14 B.R. Bohaty et al. / International Journal of Women's Dermatology 1 (2015) 13–20and Lane, 1994). Colonization coupled with minor cutaneous trauma
and/or concomitant skin disease such as atopic dermatitis can predis-
pose to infection (Bangert et al., 2012). Sites of colonization can vary
throughout the body, and they include the axillae, nares, pharynx, and
the perineal area among others (Durupt et al., 2007; Popovich and
Hota, 2008). S. pyogenes tends to only infect areas of the skin where
the barrier has been disrupted (Habif, 2004; Steer et al., 2007).
The presentation of impetigo can vary, with both bullous and
nonbullous forms making up the spectrum of the disease. Nonbullous
impetigo is the primary presenting morphology, making up 70% of
cases, and presents with erythematous papules and superﬁcial vesicles
that often transition into golden-yellow-crusted (honey-crusted)
plaques as they rupture and heal (George and Rubin, 2003). Acral and
face involvement is common in the nonbullous form, whereas bullous
impetigo often presents in the intertriginous areas of the body
(e.g., axillae, neck) with vesicles and ﬂaccid ﬂuid-ﬁlled bullae that prog-
ress to erosions and crusting (Cole and Gazewood, 2007; Koning et al.,
2012). Impetigo is contagious, and the spread of the pathogenic bacteria
from person to person is via autoinoculation and fomites (Cole and
Gazewood, 2007). Close contacts are at risk for acquiring infection,
while other risk factors for transmission include poor hygiene, a
humid environment, trauma, and atopy (Bangert et al., 2012). Most dis-
ease is self-limited even in the absence of antibacterial treatment, al-
though rare complications such as blood, bone, joint, and lung
infections do occur (Paller and Mancini, 2006). Poststreptococcal glo-
merulonephritis also has been shown to develop after cases of impetigo
caused by S. pyogenes (Paller and Mancini, 2006).
In the setting of localized impetigo infections, the possibilities for
autoinoculation, systemic spread and complications, and the spread of
disease to close contacts has led many health care providers to treat
early with antimicrobial and antibacterial agents. Treatment failures
with topical and oral agents are not uncommon and have been shown
to be secondary to bacterial resistance (Lee et al., 2005). Resistant
strains of bacteria known to cause impetigo, such as methicillin-
resistant S. aureus (MRSA) and macrolide-resistant S. pyogenes, are be-
coming more prevalent in an era in which the development and Food
and Drug Administration approval of new antibacterial agents has
slowed (Kaplan, 2008; Kaplan et al., 2005; Spellberg et al., 2004). A
study of patients presenting to the emergency departments of 11
major medical centers identiﬁed community-acquired MRSA as the
most common identiﬁable cause of skin and soft tissue infections,
with an overall prevalence of MRSA at 59% (Moran et al., 2006). A
more recent study of multiple centers throughout the United Stated
found that MRSA was the cause of 78% of the staphylococcal-related in-
fections of the cutaneous and soft tissues (Gorwitz, 2008). Another re-
cent study, in otherwise healthy children aged 3 months to 18 years
treated at Texas Children’s Hospital (Houston, TX) for suspected
S. aureus skin and soft tissue infection or invasive infection, examined
MRSA colonization rates. MRSA was isolated from clinical cultures in
63% to 70% of children (Kaplan et al., 2014). Resistance to mupirocin
among the S. aureus isolates tested in one international study was
found to be 6.8% in the United States (Deshpande et al., 2002). Another
study performed in the Unites States found mupirocin resistance as
high as 24% (Raju et al., 2008). Other studies have reported an increas-
ing resistance of MRSA isolates to common topical agents such as
mupirocin and sodium fusidate (Oranje et al., 2007). Further studies
have shown multi-drug resistance among MRSA strains (Silverberg
and Block, 2008).
Past management options for patients affected by impetigo are
many and include active nonintervention (observation), sodium hypo-
chlorite baths, over-the-counter topical agents, topical antibacterials,
and oral antibacterials (Bangert et al., 2012). Shorter duration of disease
has been shown with several treatment options (Bernard, 2008; Cole
and Gazewood, 2007; Koning et al., 2012), although observation alone
may be reasonable given that spontaneous resolution without sequelae
is common inside of a few weeks without treatment (Bangert et al.,2012). More studies are needed to determine if treating persons who
are actively infected can lead to a decrease in the incidence of
poststreptococcal glomerulonephritis compared with observation
alone. The risk for transmission of infection to close contacts and sys-
temic spread is not altered by active nonintervention. For this reason,
among others, topical antibacterial medications remain the treatment
of choice for those with limited skin disease (Bangert et al., 2012). The
two most common agents that have been used by physicians to treat
impetigo throughout the world are fusidic acid and mupirocin
(Bangert et al., 2012). Mupirocin has been prescribed to eradicate colo-
nization with S. aureus in the nares and works by inhibiting bacterial
isoleucyl-t-RNA synthetase, while fusidic acid exerts its antibacterial ac-
tion through inhibition of bacterial protein synthesis (Bangert et al.,
2012). Emerging resistance to these traditional topical agents among
the bacterial pathogens responsible for impetigo has sparked an explo-
ration for newer and better topical treatments.
In 2007, topical retapamulin ointment 1% (Altabax; GlaxoSmithKline,
Research Triangle Park, NC) was developed to help battle antibacterial
resistance and is currently approved for use in adults and pediatric pa-
tients aged 9 months and older for the topical treatment of impetigo
(up to 100 cm2 in total area in adults or 2% total body surface area in pe-
diatric patients aged 9 months or older) due to S. aureus (methicillin-
susceptible isolates only) or S. pyogenes (GlaxoSmithKline, Altabax
prescribing information, 2007; Rittenhouse et al., 2006). Retapamulin
ointment 1% was the ﬁrst member of the pleuromutilan class of antibac-
terial agents and possesses a threefold mode of action that helps to pre-
vent the development of drug resistance (Bangert et al., 2012; Yan et al.,
2006). Retapamulin ointment 1% has a good safety proﬁle due to itsmin-
imal systemic absorption and has minimal side effects, such as local irri-
tation at the application site (Dhingra et al., 2013). Previous clinical trials
have shown the efﬁcacy of retapamulin ointment 1% in the treatment of
impetigo. One randomized, observer-blinded, noninferiority study
comparing retapamulin ointment 1% to sodium fusidate 2% for the treat-
ment of impetigo found similar effectiveness rates for retapamulin
ointment 1% and sodium fusidate consisting of 99.1% and 94% respective-
ly (p= .003) (Oranje et al., 2007). Other clinical studies have compared
mupirocin cream or retapamulin ointment 1% to oral cephalexin in the
treatment of secondarily infected dermatitis and found equally high suc-
cess rates; however, patients and their parents preferred topical treat-
ment over oral treatment (Bangert et al., 2012; Parish et al., 2006; Rist
et al., 2002). In vitro studies have shown no differences in retapamulin
ointment 1% susceptibility between methicillin-resistant and
methicillin-susceptible strains of S. aureus; however, clinical data to sup-
port the use of retapamulin ointment 1% in the treatment of methicillin-
resistant S. aureus remains incomplete (Traczewski and Brown, 2008;
Woodford et al., 2008). Data on the prevalence of retapamulin resistance
are limited. However, one study of S. aureus isolates from skin and soft
tissue infections in children found that 9.5% of the screened isolates ex-
hibited retapamulin resistance, of which 57.9% were MRSA (McNeal
et al., 2014). Although epidemiological data speciﬁc to the Houston
area is limited (Kaplan et al., 2014), an increased prevalence of MRSA in-
fections has been noted over the past several years in patients seen at
The University of Texas Houston dermatology clinic. The purpose of
this study was to document the clinical and bacteriological efﬁcacy of
retapamulin ointment 1% in the treatment of patients with cutaneous
bacterial infections such as impetigo, folliculitis, and otherminor soft tis-
sue infections, including secondarily infected eczema presumed to be
caused by methicillin-resistant S. aureus.
Materials and methods
Study design and objectives
This was a prospective, nonrandomized, uncontrolled, open label,
single center trial to evaluate the efﬁcacy of retapamulin ointment 1%
at treating impetigo, folliculitis, and other minor soft tissue infections
able 1
aseline demographic and clinical characteristics.
Characteristic Retapamulin ointment 1%
(n = 38)
Age, years, mean (SD) All patients 18.5 (25.66)
Age, n (%) b 18 28 (73.7%)
≥ 18 10 (26.3%)
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study was approved by the institutional review board at The University
of TexasHealth ScienceCenter at Houston, also known as theCommittee
for the Protection of Human Subjects. Patients were recruited from The
University of Texas Health Science Center at Houston outpatient derma-
tology clinic. The study was conducted in accordancewith Good Clinical
Practice and the guiding principles of the Declaration of Helsinki.Sex, n (%) Female 27 (71.1%)
Male 11 (28.9%)
Race, n (%) Eastern European descent 18 (47.4%)
African American 10 (26.3%)
Hispanic 5 (13.2%)
Asian 4 (10.5%)
Other 1 (2.6%)
Baseline pathogen,
n (%)
All pathogens n = 36
Staphylococcus aureus 26 (72.2%)
MRSA⁎ (7, 19.4%)
MSSA (19, 52.8%)
Streptococcus pyogenes 2 (5.5%)
Other Streptococcus species 1 (2.8%)
Coagulase negative
Staphylococcus
7 (19.4%)
No growth n = 2
⁎ The seven patientswithMRSA include six pediatric (aged b 18 years) patients and one
dult (aged ≥ 18 years) patient. Three patients were male and four were female.Participants
Male or female patients aged 9 months to 98 years, diagnosed with
impetigo, folliculitis, or minor soft tissue infection (including secondar-
ily infected eczema presumed to be caused by S. aureus) suitable for
treatment with a topical antibiotic, were eligible for inclusion. If the pa-
tient was a female of childbearing potential, a negative urine pregnancy
test before performing any study-related procedures was required. Ex-
clusion criteria were as follows: use of topical antibacterial medication
to the area being treatedwithin the last 48 hours; enrollment in another
clinical trial within the last 30 days; signs of systemic infection (such as
fever) or evidence of abscess or cellulitis at the site to be treated; pres-
ence of a bacterial skin infection that, in the opinion of the investigator,
would not be appropriately treated by a topical antibiotic; oral antibiotic
use within the last 7 days; known sensitivity to the study medication;
and current pregnancy or breastfeeding.Screened
N=50
Received at least 1 
dose of 
retapamulin (CLI)
N=38
Withdrew Consent
N=1
Completed Study 
N=37
Culture Positive 
(MIC) N=35
MRSA Isolated 
(RES) N=7
Other Species 
Isolated N=28
No Growth
N=2
Screen Fail
N=12
Fig. 1. Flow diagram of patient progress throughout the trial: CLI= all patients enrolled in
the studywho received at least 1 application of studymedication,MIC=all patients in CLI
who had a pathogen isolated from the treatment area at baseline uponmicrobiologic test-
ing, and RES= all patients in CLI who hadMRSA isolated as a baseline pathogen (primary
efﬁcacy population).T
B
aInterventions
Patients attended up to 2 study clinic visits over a period of 5 to 7
days (Fig. 1). Treatment was started at the ﬁrst clinic visit. The infected
area was ﬁrst cleaned with a sterile nonantibacterial wipe. Study per-
sonnel then provided the patient (or parent/guardian if applicable)
with a 10 g tube of topical retapamulin ointment 1% (10mg retapamulin
per 1 gm of ointment), a study diary to document study drug applica-
tions, and instructions for basic wound care and application of study
drug. Patients were instructed to apply a thin layer of retapamulin oint-
ment 1% to the infected lesion(s) twice daily for 5 days, for a total of 10
doses, regardless of clinical improvement. Study personnel delivered
treatment at visit 1. The maximum area to be treated was 100 cm2 in
adults, and 2% of the total body surface area for pediatric patients, corre-
sponding with a maximum retapamulin ointment 1% dose of approxi-
mately 1 g. Sterile bandage or gauze use to cover the treatment area
was allowed for all patients and required for children who could have
potentially put the treated lesion(s) in their mouth. Patients were
allowed towithdraw themselves from the study at any time. The inves-
tigator could withdraw a patient due to failure of therapy or worsening
signs of infection at any time and was available to provide them with
oral antibiotics or other treatment as appropriate. Patients requiring
withdrawal from the study were requested to follow-up within 48
hours of when the studymedication would have been completed to re-
cord safety and adverse event data. Patients received an initial clinicalTable 2
Clinical and microbiological responses by grade at follow-up: efﬁcacy outcomes (primary
efﬁcacy population, n = 7).
Clinical Response
(Grade)
MRSA, n/N
(%)
Microbiologic Response (Grade) MRSA, n/N
(%)
1. Clinical success 5/7 (71%) 1. Microbological eradication 0/7 (0%)
2. Clinical
improvement
2/7 (29%) 2. Presumed microbiological
eradication
5/7 (71%)
3. No change 0/7 (0%) 3. Presumed microbiological
improvement
2/7 (29%)
4. Clinical failure 0/7 (0%) 4. Microbiological persistence 0/7 (0%)
5. Unable to
determine
0/7 (0%) 5. Presumed microbiological
persistence
0/7 (0%)
6. Unable to determine 0/7 (0%)
7. New pathogen 0/7 (0%)
8. Colonization 0/7 (0%)
Table 3
Clinical and microbiological responses by grade at follow-up: efﬁcacy outcomes (MIC population, n= 35).
Clinical response (Grade) Retapamulin ointment 1%, n/N (%) Microbiologic response (Grade) Retapamulin ointment 1%, n/N (%)
1. Clinical success 23/35 (66%) 1. Microbiological eradication 1/35 (3%)
2. Clinical improvement 11/35 (31%) 2. Presumed microbiological eradication 23/35 (65%)
3. No change 0/35 (0%) 3. Presumed microbiological improvement 10/35 (28%)
4. Clinical failure 1/35 (3%) 4. Microbiological persistence 1/35 (3%)
5. Unable to determine 0/35 (0%) 5. Presumed microbiological persistence 0/35 (0%)
6. Unable to determine 0/35 (0%)
7. New pathogen 0/35 (0%)
8. Colonization 0/35 (0%)
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(day 1). To determine efﬁcacy, repeat clinical and microbiological
exams were performed during the follow-up visit (day 6–8) that was
scheduled to occur within 48 hours of ﬁnishing all 10 doses of the
retapamulin ointment 1%.
Bacteriology
Bacteriologic samples were obtained by curettage from patients at
visit 1 before initiating treatment. Swab samples were collected from
the treatment area with a preference for obtaining sufﬁcient pus or ex-
udate when present to impregnate the swab. During the post-therapy
follow-up visit, bacteriologic samples were obtained if the patient was
deemed a clinical failure or had withdrawn from the study. Isolated
pathogens were sent to a local laboratory (Microbiology Specialists,
Inc., Houston, TX) for culture and sensitivity processing according to
Clinical and Laboratory Standards Institute guidelines (Clinical and Lab-
oratory Standards Institute, 2007). Study samples thatwere culture pos-
itive for S. aureus pathogens underwent further testing to determine the
presence or absence of the Panton-Valentine leukocidin genes accord-
ing to published methodology (Johnsson et al., 2004; Lina et al., 1999;
Wolter et al., 2007).Table 4
Clinical, microbiological and therapeutic responses by prognostic factor at follow-up: efﬁcacy o
Retapamulin ointment 1% Succ
Clinical Response
Overall 23/35 (66%)
Wound area⁎ (Baseline)
≤Median (3.4) 14/19 (74%)
NMedian (3.4) 9/16 (56%)
Sex
Female 15/24 (63%)
Male 8/11 (73%)
Age
b 18 years 17/25 (68%)
≥ 18 years 6/10 (60%)
MRSA at baseline
Y 5/7 (71%)
N 18/28 (64%)
Race
White 14/17 (82%)
African American 7/9 (78%)
Hispanic 1/5 (20%)
Asian 1/4 (25%)
Baseline pathogen
Staphylococcus aureus 11/18 (61.1%)
MRSA (5/7, 71.4%)
MRSA and aged b 18 years (5/6)
MRSA and aged ≥ 18 years (0/1)
MSSA (6/11, 51.5%)
Streptococcus pyogenes 1/2 (50.0%)
Other Streptococcus species 1/1 (100%)
Coagulase negative Staphylococcus 5/7 (71.4%)
⁎ Wound area was divided into two groups by its median. Median value was chosen for conAnalysis population
An intention-to-treat analysis was performed for four populations.
The ﬁrst population (CLI) included all patients enrolled in the study
who received at least 1 application of study medication. The second
population (MIC) included all patients in CLIwhohad a pathogen isolat-
ed from the treatment area at baseline upon microbiologic testing. The
third population (RES) included all patients in CLIwhohadMRSA isolat-
ed as a baseline pathogen and serves as the primary efﬁcacy population.
The fourth population (PED) included all patients in CLI b18 years of age
at the time of study completion.
Efﬁcacy evaluations
The primary endpoint for this study was deﬁned as the clinical re-
sponse (success or failure) at follow-up in the RES population with
MRSA isolated as the baseline pathogen. Secondary endpoints included
clinical, microbiological, and therapeutic responses at follow-up (MIC,
RES, PED) comparison of wound size from baseline to follow-up (MIC,
RES, PED), comparison of signs and symptomsof infection frombaseline
to follow-up (MIC, RES, PED), and the safety and tolerability of topical
retapamulin ointment 1% based on adverse event (AE) data (CLI).utcomes (MIC population, n= 35).
ess Rate, n/N (%)
Microbiological Response Therapeutic Response
34/35 (97%) 24/35 (69%)
19/19 (100%) 15/19 (79%)
15/16 (94%) 9/16 (56%)
23/24 (96%) 15/24 (63%)
11/11 (100%) 9/11 (82%)
25/25 (100%) 18/25 (72%)
9/10 (90%) 6/10 (60%)
7/7 (100%) 5/7 (71%)
27/28 (96%) 19/24 (79%)
16/17 (94%) 14/17 (82%)
9/9 (100%) 7/9 (78%)
5/5 (100%) 2/5 (40%)
4/4 (100%) 1/4 (25%)
17/18 (94.4%) 12/18 (66.7%)
(7/7, 100%) (5/7, 71.4%)
(6/6) (5/6)
(1/1) (0/1)
(10/11, 91.0%) (7/11, 63.6%)
2/2 (100%) 1/2 (50.0%)
1/1 (100%) 1/1 (100%)
7/7 (100%) 5/7 (71.4%)
venience but may lack clinical importance.
Table 6
Skin infection rating scale (by age).
Retapamulin ointment 1%, n= 35
(MIC population)
Baseline Follow-up
Item Category Score Scale Age b 18
years
Age ≥ 18
years
Age b 18
years
Age ≥ 18
years
1 Erythema 0 Absent 0 0 7 2
1 Minimal 6 4 16 8
2 Moderate 19 6 2 0
3 Severe 0 0 0 0
2 Purulence 0 Absent 5 5 24 10
1 Minimal 12 2 1 0
2 Moderate 8 2 0 0
3 Severe 0 1 0 0
3 Crusting 0 Absent 2 0 18 7
1 Minimal 5 3 6 3
2 Moderate 16 7 1 0
3 Severe 2 0 0 0
4 Tissue
edema
0 Absent 3 0 13 6
1 Minimal 11 8 12 4
2 Moderate 11 2 0 0
3 Severe 0 0 0 0
5 Tissue
warmth
0 Absent 5 4 15 6
1 Minimal 14 6 10 4
2 Moderate 6 0 0 0
3 Severe 0 0 0 0
6 Pain 0 Absent 4 4 17 9
1 Minimal 14 5 8 1
2 Moderate 7 1 0 0
3 Severe 0 0 0 0
able 5
kin infection rating scale.
Retapamulin ointment 1%,
n= 35
(MIC population)
Item Category Score Scale Baseline n
(%)
Follow-up n
(%)
p value
1 Erythema 0 Absent 0 (0%) 9 (26%) b .00001
1 Minimal 10 (29%) 24 (69%)
2 Moderate 25 (71%) 2 (5%)
3 Severe 0 (0%) 0 (0%)
2 Purulence 0 Absent 10 (29%) 34 (97%) b .00001
1 Minimal 14 (40%) 1 (3%)
2 Moderate 10 (29%) 0 (0%)
3 Severe 1 (2%) 0 (0%)
3 Crusting 0 Absent 2 (6%) 25 (71%) b .00001
1 Minimal 8 (23%) 9 (26%)
2 Moderate 23 (65%) 1 (3%)
3 Severe 2 (6%) 0 (0%)
4 Tissue
Edema
0 Absent 3 (9%) 19 (54%) b .00001
1 Minimal 19 (54%) 16 (46%)
2 Moderate 13 (37%) 0 (0%)
3 Severe 0 (0%) 0 (0%)
5 Tissue
warmth
0 Absent 9 (26%) 21 (60%) .0027
1 Minimal 20 (57%) 14 (40%)
2 Moderate 6 (17%) 0 (0%)
3 Severe 0 (0%) 0 (0%)
6 Pain 0 Absent 8 (23%) 26 (74%) .000026
1 Minimal 19 (54%) 9 (26%)
2 Moderate 8 (23%) 0 (0%)
3 Severe 0 (0%) 0 (0%)
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at the follow-up visit using a predeﬁned scale with the following catego-
ries: (1) clinical success, (2) clinical improvement, (3) no change,
(4) clinical failure, and (5) unable to determine. Patients who were des-
ignated as clinical success as deﬁned in number 1 abovewere considered
a true “clinical success”while all others were considered a “clinical fail-
ure.” Patients were classiﬁed with an outcome of “unable to determine”
if they missed their follow-up visit or refused clinical examination.
Microbiological response was determined by the investigator at the
follow-up visit using the following microbiological outcomes:
(1) microbological eradication, (2) presumed microbiological eradica-
tion, (3) presumed microbiological improvement, (4) microbiological
persistence, (5) presumed microbiological persistence, (6) unable to
determine, (7) new pathogen, and (8) colonization. Patients who
were designatedmicrobiological eradication, presumedmicrobiological
eradication, presumedmicrobiological improvement, or colonization as
deﬁned in numbers 1, 2, 3, and 8 abovewere considered a “microbiolog-
ical success”while all others were considered “microbiological failure.”
Therapeutic response was determined from the clinical response
and themicrobiological response. Patientswho qualiﬁed as both a “clin-
ical success” and a “microbiological success”were deemed a “therapeu-
tic success,” and all others were deemed “therapeutic failures.”
Wound size area was determined by measuring the greatest length
of the wound in two perpendicular dimensions with a standard metric
ruler. The two measurements were multiplied together to provide an
estimate of the overall wound size. Surrounding erythema was not in-
cluded in the measurement.
Signs and symptoms of the lesions were assessed based on the fol-
lowing factors: erythema, purulence, crusting, edema, warmth, and
pain. Each factorwas classiﬁed as one of the following: absent, minimal,
moderate, or severe.
Samples size and statistical methods
The study was a prospective, nonrandomized, uncontrolled, open
label, and single center trial to evaluate the efﬁcacy of retapamulin oint-
ment 1% at treating impetigo, folliculitis, and other minor soft tissue in-
fections in children and adults. A total of 50 patients were recruited
between April 2008 and November 2012. Seven of the 38 patients in
the CLI safety population were culture positive at baseline for MRSA
and qualiﬁed for the primary efﬁcacy (RES) population.
Descriptive statistics were summarized for all demographic charac-
teristics, baseline variables, and three responses (clinical, microbiologi-
cal, and therapeutic). Univariate logistic regression analyses were
performed to see how clinical response was related to several prognos-
tic factors, including wound sizes at different visits, sex, age, and the
presence ofMRSA. Odds ratio (OR)with 95% conﬁdence intervalwas re-
ported for each factor. The comparison of wound size change at follow-
up visit to baselinewas conducted by paired t test. A p value of b .05was
considered statistically signiﬁcant for themain effect. S-plus/R software
was used for all statistical analyses.
Results
Study population
A total of 50 patients were recruited between April 2008 and No-
vember 2012. The disposition of patients in the study is presented in
Fig. 1. The 38 patients who received retapamulin ointment 1% made
up the CLI safety population, and 35 of these patients were culture pos-
itive, making up the MIC population. Of the 37 patients who completed
the study, only 7 were MRSA positive and qualiﬁed for the primary efﬁ-
cacy population (RES). Twelve patients were culture negative and,
therefore, did not qualify for any efﬁcacy analysis. Only one patient
(2.6%) withdrew from the study before completing all study proceduresT
Sdue to a withdrawal of consent. The demographic characteristics of pa-
tients who received treatment are presented in Table 1.
Bacteriology
S. aureus was the most frequently isolated pathogen at baseline
(72.2%); 19.4% (7 of 36) of patientswere culture positive forMRSAmak-
ing up the primary efﬁcacy population (Table 1).
Table 7
Skin infection rating scale (primary efﬁcacy population).
MRSA, n= 7
Item Category Score Scale Baseline Follow-up
1 Erythema 0 Absent 0 2
1 Minimal 7 5
2 Moderate 0 0
3 Severe 0 0
2 Purulence 0 Absent 2 7
1 Minimal 2 0
2 Moderate 3 0
3 Severe 0 0
3 Crusting 0 Absent 1 7
1 Minimal 2 0
2 Moderate 3 0
3 Severe 1 0
4 Tissue edema 0 Absent 0 2
1 Minimal 2 5
2 Moderate 5 0
3 Severe 0 0
5 Tissue warmth 0 Absent 1 4
1 Minimal 3 3
2 Moderate 3 0
3 Severe 0 0
6 Pain 0 Absent 1 6
1 Minimal 3 1
2 Moderate 3 0
3 Severe 0 0
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The data for the primary endpoint for this study—the clinical re-
sponse (success or failure) at follow-up in the RES population with
MRSA isolated as the baseline pathogen—are summarized in Table 2.
Secondary endpoints included clinical responses at follow-up for RES
(Table 2), MIC (Table 3), and PED (Table 4).
Microbiological efﬁcacy
Secondary endpoints included microbiological responses at follow-
up for the RES (Table 2), MIC (Table 3), and PED (Table 4) populations,
as well as therapeutic responses at follow-up for RES, MIC, and PED
(Table 4).
Skin infection rating scale
Other secondary endpoints included comparison of signs and symp-
toms of infection from baseline to follow-up for the MIC, PED, and RES
populations (Tables 5–7). Table 5 describes skin infection rating scales
(SIRS) along with number of patients (reported as frequency and per-
centage) at baseline and follow-up visit. A decreasing trend in score be-
tween two visits was observed in all infection types. For instance, in
erythema, 71% of patients had score 2 (moderate) at baseline, whereas
69%had score 1 (minimal) at follow-up (Table 5). However, the interpre-
tation here needs to be cautious, because the score at follow-up visit and
baseline are correlated. In the last column, p values from the χ2 test areTable 8
Comparison of percent decrease in wound size from baseline to follow-up.
MIC population Statistics Baseline
Total (n = 35) Mean (SD) 14.43 (2
Median 3.40
Age b18 years (n = 25) Mean (SD) 18.61 (2
Median 4.80
Age ≥18 years (n = 10) Mean (SD) 3.98 (4.4
Median 2.75
MRSA (n = 7) Mean (SD) 20.61 (2
Median 14.0
The p value from paired t test that compares logarithms of wound size at visits 1 and 2 is b .000provided to compare categorized scores at follow-upwith scores at base-
line, which indicates that patients signiﬁcantly improved over time in all
categories (Table 5). Table 6 summarizes SIRS data by age group, and
Table 7 lists the SIRS data for the primary efﬁcacy population.
Wound size analyses
Another secondary endpoint compared the wound areas at baseline
and follow-up for the RES, PED, and MIC populations (Table 8). Their
mean wound areas were 14.43 cm2 (baseline) and 4.31 cm2 (follow-
up), and their log-transformations were tested with paired t test, yield-
ing p b .00001, which conﬁrms that wound area at visits 1 and 2 is sig-
niﬁcantly different. For PED subgroup aged b 18 years, p= .0002, and
for the subgroup with age ≥ 18 years, p= .002, using paired t test. For
the RES (MRSA+) group, p= .0156. In all cases,wound sizes at baseline
and follow-up are signiﬁcantly different.
Safety
The proportion of patients who experienced treatment-emergent
AEs during the studywas10.5% (Table 9). AEs included burning at appli-
cation site (n= 1), upper respiratory infection (n= 1), furuncle (n=
1), cough (n = 1), and a rash at a site other than the application site
(n = 1). All AEs were mild or moderate in severity. Only one patient
withdrew from the study due to an AE (2.6%; Table 9). No serious AEs
were reported during the study.
Exploratory analyses
Table 4 presents the number of patients and success rates for three
responses (clinical, microbiological, and therapeutic) by several prog-
nostic factors. To further evaluate the relationship between some of
these prognostic factors and clinical response, logistic regression was
performed, and the results were summarized in Table 10, which focuses
on the MIC population. Wound area was divided into two groups by its
median value, which was chosen for convenience but may lack clinical
importance. The OR associated with wound area at baseline is 2.60,
which indicates that the odds of experiencing successful clinical re-
sponse for patients with wound size at baseline b 3.4 cm2 is expected
be 2.60 times higher than the odds of experiencing successful clinical re-
sponse for patientswithwound size at baseline≥ 3.4 cm2. However, the
related p value is .198, and wound size at baseline is not a statistically
signiﬁcant predictor of clinical response. No signiﬁcance was found for
the other variables.
Discussion
The objective of this study was to assess the clinical and bacteriolog-
ical efﬁcacy of topical retapamulin ointment 1% in the treatment of pa-
tients with cutaneous bacterial infections, such as impetigo, folliculitis,
and otherminor soft tissue infections, including secondarily infected ec-
zema presumed to be caused by MRSA. The data for the primary end-
point for this study—the clinical response (success or failure) atFollow-up Mean change % (SD)
5.38) 4.31 (17.71) −71.3% (36.0%)
0.30
9.01) 5.6 (20.92) −73.6% (36.5%)
0.1
2) 1.09 (1.37) −65.6% (35.8%)
0.5
4.83) 2.59 (3.21) −87.8% (19.1%)
0.3
01. Mean change (%) was deﬁned as (size at baseline – size at follow-up)/size at baseline.
Table 9
Number of patients reporting adverse events withdrawing from study due to adverse
events.
Retapamulin ointment 1%, n/N (%)
Patients reporting any AE 4/38 (10.5%)
Patients withdrawn due to AE 1/38 (2.6%)
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as the baseline pathogen—was not sufﬁciently powered to demonstrate
signiﬁcance; however, outcomes were excellent overall for this popula-
tionwith 7 of 7 patients demonstrating either clinical success or clinical
improvement at follow-up. It remains unclear why most patients who
tested positive for S. aureus were methicillin-sensitive. This ﬁnding is
contrary to data from previous clinical trials (Gorwitz, 2008; Moran
et al., 2006) and the investigators own clinical experience, in which
MRSA has been found to represent the majority pathogen.
An uneven distribution between age groups (the proportion of pa-
tients aged b 18 years was 73.7%, and the proportion of those aged ≥
18 years was 26.3%) coupled with a small overall sample size (n= 35)
impedes the development of conclusions regarding the effect of age on
clinical, microbiologic, and therapeutic responses. Barring the lack of sig-
niﬁcance due to the small total sample size for patients who received
treatment and were culture positive (MIC; n= 35), the overall success
rates were favorable for clinical, microbiologic, and therapeutic re-
sponses with values of 66%, 97%, and 69%, respectively. Subgroup analy-
ses of these responses for PED and RES found excellent success rates
overall as well.
Exploratory analyses examining correlation of several prognostic
factors (wound size, sex, age, and pathogen) with clinical responses
were unable to show clinical signiﬁcance. The OR associated with
wound area at baseline was 2.60, which indicates that the odds of
experiencing successful clinical response for patients with wound size
at baseline b 3.4 cm2 is expected be 2.60 times higher than the odds of
experiencing successful clinical response for patients with wound size
at baseline ≥ 3.4 cm2. However, the related p value was .198, and
wound size at baseline is not a statistically signiﬁcant predictor of clin-
ical response. The odds ratio comparing S. aureus versus no S. aureus
was .76, and the odds ratio from MRSA was 1.39; that is, clinical re-
sponse may be different across MRSA and MSSA but the difference is
not signiﬁcant.
The safety proﬁle of topical retapamulin ointment 1% appears favor-
able given the low number of AEs observed during the study. Of those
that occurred, all were mild or moderate in severity, with no serious
AEs reported. This favorable safety proﬁle is consistent with data from
previous studies.
Conclusion
Study design and execution limits the conclusions that can be drawn
regarding the efﬁcacy of topical retapamulin 1% ointment in the treat-
ment of cutaneous bacterial infections, including those caused by S.Table 10
Odds ratio with 95% conﬁdence interval investigating factors associated with clinical re-
sponse by univariate logistic regression.
Variable Odds ratio 95% conﬁdence
interval
p value
Wound size (baseline)
b 3.4 vs. ≥ 3.4 (ref) 2.60 (0.607, 11.1) .198
Male vs. female (ref) 1.60 (0.335, 7.639) .556
Aged b 18 years vs. aged ≥ 18 years (ref) 1.42 (0.310, 6.469) .653
MRSA: yes vs. no (ref) 1.39 (0.226, 8.508) .722
S. aureus: yes vs. no (ref) 0.76 (0.156, 3.698) .736
Abbreviations: ref, reference.aureus and MRSA. Small sample size, lack of a placebo comparator,
single-site design, and failure to ensure microbiological eradication
with a repeat culture post-treatment are limitations for this study. Nev-
ertheless, this study supports the use of topical retapamulin 1% oint-
ment in the treatment of cutaneous bacterial infections, particularly
those caused by S. aureus, including MRSA.
Acknowledgments
We acknowledge the support provided by the Biostatistics/Epidemi-
ology/Research Design (BERD) component of the Center for Clinical and
Translational Sciences (CCTS) for this project. CCTS is mainly funded by
the NIH Centers for Translational Science Award (NIH CTSA) grant (UL1
RR024148), awarded to University of Texas Health Science Center at
Houston in 2006 by the National Center for Research Resources
(NCRR) and its renewal (UL1 TR000371) by the National Center for Ad-
vancing Translational Sciences (NCATS). The content is solely the re-
sponsibility of the authors and does not necessarily represent the
ofﬁcial views of NCRR or the NCATS.
References
Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a re-
view. Pediatr Dermatol 2012;29:243–8.
Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis
2008;21:122–8.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Sus-
ceptibility Testing. Seventeenth Informational Supplement.Wayne, PA: CLSI1-56238-
625-5; 2007(CLSI Document M100-S17).
Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician 2007;75:
859–64.
Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994;11:293–303.
Deshpande LM, Fix AM, Pfaller MA, Jones RN, SENTRY Antimicrobial Surveillance Program
Participants Group. Emerging elevated mupirocin resistance rates among staphylo-
coccal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correla-
tions of results from disk diffusion, Etest and reference dilution methods. Diagn
Microbiol Infect Dis 2002;42:283–90.
Dhingra D, Parakh A, Ramachandran S. Retapamulin: a newer topical antibiotic. J Postgrad
Med 2013;59:127–30.
Durupt F, Mayor L, Bes M, Reverdy ME, Vandenesch F, Thomas L, et al. Prevalence of
Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J
Dermatol 2007;157:1161–7.
George A, Rubin G. A systematic review and metaanalysis of treatments for impetigo. Br J
Gen Pract 2003;53:480–7.
GlaxoSmithKline. ALTABAX prescribing information. Research Triangle Park, NC:
GlaxoSmithKline; 2007.
Gorwitz RJ. Community-associated methicillin-resistant Staphylococcus aureus: epidemi-
ology and update. Pediatr Infect Dis J 2008;27:925–6.
Habif T. Bacterial infections. Clinical dermatology. 4th ed. Philadelphia: Mosby, Inc; 2004.
Johnsson D, Mölling P, Strålin K, Söderquist B. Detection of Panton-Valentine leukocidin
gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological as-
pects. Clin Microbiol Infect 2004;10:884–9.
Kaplan SL. Commentary: prevention of recurrent staphylococcal infections. Pediatr Infect
Dis J 2008;27:935–7.
Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, et al.
Three-year surveillance of community-acquired Staphylococcus aureus infections in
children. Clin Infect Dis 2005;40:1785–91.
Kaplan SL, Forbes A, HammermanWA, Lamberth L, Hulten KG, Minard CG, et al. Random-
ized trial of “bleach baths” plus routine hygienic measures vs routine hygienic mea-
sures alone for prevention of recurrent infections. Clin Infect Dis 2014;58:679–82.
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler CC,
Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database of Sys-
tematic Reviews 2012;1. http://dx.doi.org/10.1002/14651858 Art. No.: CD003261.
Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin struc-
ture infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:
283–95.
Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of
Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infec-
tions and pneumonia. Clin Infect Dis 1999;29:1128–32.
McNeal JC, Hulten KG, Kaplan SL, Mason EO. Decreased susceptibilities to retapamulin,
mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin
and soft tissue infections in otherwise healthy children. Antimicrob Agents
Chemother 2014;58:2878–83.
Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al.
Methicillin-resistant S. aureus infections among patients in the emergency depart-
ment. N Engl J Med 2006;355(7):666–74.
Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical
retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a ran-
domized, observer-blinded, noninferiority study. Dermatology 2007;215:331–40.
20 B.R. Bohaty et al. / International Journal of Women's Dermatology 1 (2015) 13–20Paller AS, Mancini AJ. Hurwitz clinical pediatric dermatology: a textbook of skin disorders
of childhood and adolescence. 3rd ed. Philadelphia: Elsevier; 2006 366–7.
Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, et al. Topical
retapamulin ointment (1%, wt⁄wt) twice daily for 5 days versus oral cephalexin
twice daily for 10 days in the treatment of secondarily infected dermatitis: results
of a randomized controlled trial. J Am Acad Dermatol 2006;55:1003–13.
Popovich KJ, Hota B. Treatment and prevention of community-associated methicillin-
resistant Staphylococcus aureus skin and soft tissue infections. Dermatol Ther 2008;
21:167–79.
Raju V, Mongkolrattanothai K, Mankin P, Gray B. Surveillance for mupirocin resistance
among MRSA clinical isolates. P11 poster presented at: 2008 Annual Conference on
Antimicrobial Resistance; 2008.
Rist T, Parish LC, Capin LR, Sulica V, Bushnell WD, Cupo MA. A comparison of the efﬁcacy
and safety of mupirocin cream and cephalexin in the treatment of secondarily infect-
ed eczema. Clin Exp Dermatol 2002;27:14–20.
Rittenhouse S, Biswas S, Broskey J, McCloskey L, Moore T, Vasey S, et al. Selection of
retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother
2006;50:3882–5.
Rortveit S, Rortveit G. Impetigo in epidemic and nonepidemic phases: an incidence study
over 4(1⁄2) years in a general population. Br J Dermatol 2007;157:100–5.Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis
and current treatment options in the United States. Clin Pediatr (Phila) 2008;47:211–9.
Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr JE. In antimicrobial drug develop-
ment: implications for the future. Clin Infect Dis 2004;38:1279–86.
Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J
Paediatr Child Health 2007;43:203–13.
Traczewski MM, Brown SD. Proposed MIC and disk diffusion microbiological cutoffs and
spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob
Agents Chemother 2008;52:3863–7.
Wolter DJ, Tenover FC, Goering RV. Allelic variation in genes encoding Panton-Valentine
leukocidin from community-associated Staphylococcus aureus. Clin Microbiol Infect
2007;13:827–30.
Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin
against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J
Antimicrob Chemother 2008;62:766–8.
Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemical charac-
terization of the interactions of the novel pleuromutilin derivative retapamulin with
bacterial ribosomes. Antimicrob Agents Chemother 2006;50:3875–81.
Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and
other uncomplicated superﬁcial skin infections. Drugs 2008;68:855–73.
